Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 9—September 2018
Research Letter

Borrelia miyamotoi Disease in an Immunocompetent Patient, Western Europe

Dieuwertje Hoornstra1Comments to Author , Joris Koetsveld1, Hein Sprong, Alexander E. Platonov, and Joppe W. Hovius
Author affiliations: Academic Medical Center, Amsterdam, the Netherlands (D. Hoornstra, J. Koetsveld, J.W. Hovius); National Institute for Public Health and the Environment, Bilthoven, the Netherlands (H. Sprong); Central Research Institute of Epidemiology, Moscow, Russia (A.E. Platonov)

Cite This Article


Borrelia miyamotoi disease is a hard tick–borne relapsing fever illness that occurs across the temperate climate zone. Human B. miyamotoi disease in immunocompetent patients has been described in Russia, North America, and Japan. We describe a case of B. miyamotoi disease in an immunocompetent patient in western Europe.

A 72-year-old woman in the Netherlands sought treatment in her third day of fever (<38.6°C) and reported myalgia, arthralgia, headache, and a 2.5-kg weight loss. Three weeks earlier she had noticed a tick bite after gardening. Several days later, an erythematous lesion appeared, increasing to palm size within 1.5 weeks and dissolving in a similar period. Full medical history was not suggestive of other causes of fever. Her previous medical history included cervical carcinoma and breast cancer, curatively treated.

Physical examination showed a moderately ill patient with a temperature of 36.7°C, heart rate of 59 bpm, blood pressure of 100/72 mmHg, an erythematous skin lesion (1.5 cm in diameter) on the thigh, and mild generalized lymphadenopathy. Initial laboratory tests revealed increased C-reactive protein (22.7 mg/L), leukopenia (2.1 × 109 cells/L), elevated monocytes (11%), and thrombocytopenia (144 × 109 platelets/L) (reference ranges in Technical Appendix Table 1). All other test results, including urinalysis, were unremarkable. Molecular tests of blood and skin biopsy and serologic testing for Borrelia burgdorferi sensu lato and syphilis were repeatedly negative, except for a C6 EIA IgM/IgG seroconversion (Immunetics, Boston, MA, USA) in convalescent-phase serum samples that was positive but could not be confirmed by either IgM or IgG immunoblot (Mikrogen, Neuried, Germany) (Technical Appendix Table 2). We did not admit the patient to the hospital, and we did not initiate antimicrobial drug treatment because her symptoms had largely resolved. At a 2-month follow-up visit, the patient had fully recovered, and laboratory test results were normal.

On the basis of the patient’s description, we suspect that she was bitten by an Ixodes ricinus tick, the most prevalent tick species in western Europe (1), which can potentially carry several tickborne pathogens: Borrelia burgdorferi s.l., B. miyamotoi, Rickettsia helvetica and R. monacensis, Anaplasma phagocytophilum, Babesia divergens and B. microti, Neoehrlichia mikurencis, and tick-borne encephalitis virus (2). Specific molecular and serologic diagnostic tests for all of these pathogens were negative, expect for 1 (false-positive) tick-borne encephalitis virus IgM ELISA result in convalescent-phase serum samples (Technical Appendix Table 2).

B. miyamotoi, a relapsing fever Borrelia species uniquely found in Ixodes spp. ticks in Eurasia and North America, is the causative agent of Borrelia miyamotoi disease (BMD), a tickborne febrile disease (3,4). Diagnosis of BMD relies on detection of spirochetes by quantitative PCR of blood and experimental serology based on glycerophosphodiester phosphodieasterase (GlpQ) antigen detection (3,5). GlpQ is present in relapsing fever Borrelia but not in B. burgdorferi s.l. and therefore can discriminate between the 2 types (4). In a well-described cohort of PCR-positive patients in Russia, characteristic clinical symptoms were fever, myalgia, nausea, and headaches; laboratory findings showed thrombocytopenia and diffuse organ damage (3).


Thumbnail of Results of GlpQ and variable major proteins (Vmps) IgM and IgG ELISA and confirmatory Western blot tests in testing of 72-year-old woman in the Netherlands who showed evidence of Borrelia miyamotoi disease. A) Anti-GlpQ and anti–Vmps IgM ELISA results representative of 3 individual ELISAs. B) Confirmatory IgM Western blot results of samples taken at 3 different time points with recombinant proteins. C) Anti-GlpQ and anti–Vmps IgG ELISA results representative of 3 individual ELISAs.

Figure. Results of GlpQ and variable major proteins (Vmps) IgM and IgG ELISA and confirmatory Western blot tests in testing of a 72-year-old woman in the Netherlands who showed evidence of Borrelia...

In this patient, results of pan–relapsing fever Borrelia PCR and B. miyamotoi–specific PCR (6) of blood drawn at the day of clinical visit were negative. However, the fever and symptoms had subsided, which probably impeded these direct diagnostic tests. We tested for anti-GlpQ and anti–variable major proteins (Vmps) IgM and IgG using ELISA and Western blot in serum samples taken on the day of the hospital visit (3 days after disease onset), after 5 weeks (38 days), and after 3 months (88 days). Results demonstrated a clear seroconversion for predominantly IgG against GlpQ (Figure). We had previously shown that Vmps are highly immunogenic in patients with BMD (7) and that the presence of antibodies against GlpQ combined with antibodies against Vmps had 100% specificity for IgM and 98.3% for IgG (8). In this case, we could demonstrate antibodies against multiple Vmps over time (Figure). Finally, our findings were further confirmed by preferential IgM and IgG reactivity to lysates of the B. miyamotoi strain HT31 (tick isolate, Japan) and Izh-16 (clinical isolate, Russia) compared with reactivity to the B. afzelii strain PKo (skin isolate, Germany) and B. hermsii HS-1 (tick isolate, United States) control lysates (Technical Appendix Figure).

These findings, combined with the established presence of B. miyamotoi in I. ricinus ticks throughout Europe, clinical presentation, and laboratory findings, strongly suggest that B. miyamotoi was the causative agent of the patient’s symptoms. That the patient recovered even without antimicrobial treatment is consistent with a recent BMD case described in the United States (9). Because of the initial skin rash, we did not completely rule out B. burgdorferi s.l. co-infection; however, prior evaluation by an independent dermatologist, a negative B. burgdorferi s.l. immunoblot despite high C6 reactivity, and a negative PCR on DNA obtained from the skin biopsy argue against co-infection. Regardless, the clinical picture of fever and mild leukopenia and thrombocytopenia is compatible with BMD and not with Lyme borreliosis. Of interest, C6 reactivity in combination with a negative B. burgdorferi s.l. immunoblot has been described in BMD patients in the United States (10).

This case identifies B. miyamotoi as an emerging tickborne pathogen in western Europe. Because of the widespread presence of multiple other tickborne pathogens across Europe, more attention and awareness for other tickborne diseases is warranted.

Dr. Hoornstra and Dr. Koetsveld are PhD students at the University of Amsterdam at the Department of Infectious Diseases in Professor Joppe W. Hovius’s laboratory. They focus on tickborne pathogens, and their work has been key in research on B. miyamotoi disease.



We thank Barbara Johnson and Volker Fingerle for providing B. miyamotoi strain HT31. Furthermore, we thank Alex Wagemakers, Tal Azagi, and Bob de Wever for their contributions to the manuscript.

This study was supported by ZonMW as part of the project “Ticking on Pandora’s Box, a study into tickborne pathogens in Europe” (project no. 50-52200-98-313) to D.H. and J.W.H. The contribution of A.E.P. was supported by a grant of the Russian Science Foundation (project 15-15-00072).



  1. Steere  AC, Strle  F, Wormser  GP, Hu  LT, Branda  JA, Hovius  JW, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. DOIPubMedGoogle Scholar
  2. Michelet  L, Delannoy  S, Devillers  E, Umhang  G, Aspan  A, Juremalm  M, et al. High-throughput screening of tick-borne pathogens in Europe. Front Cell Infect Microbiol. 2014;4:103. DOIPubMedGoogle Scholar
  3. Platonov  AE, Karan  LS, Kolyasnikova  NM, Makhneva  NA, Toporkova  MG, Maleev  VV, et al. Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis. 2011;17:181623. DOIPubMedGoogle Scholar
  4. Molloy  PJ, Telford  SR III, Chowdri  HR, Lepore  TJ, Gugliotta  JL, Weeks  KE, et al. Borrelia miyamotoi disease in the northeastern United States: a case series. Ann Intern Med. 2015;163:918. DOIPubMedGoogle Scholar
  5. Krause  PJ, Narasimhan  S, Wormser  GP, Rollend  L, Fikrig  E, Lepore  T, et al. Human Borrelia miyamotoi infection in the United States. N Engl J Med. 2013;368:2913. DOIPubMedGoogle Scholar
  6. Hovius  JW, de Wever  B, Sohne  M, Brouwer  MC, Coumou  J, Wagemakers  A, et al. A case of meningoencephalitis by the relapsing fever spirochaete Borrelia miyamotoi in Europe. Lancet. 2013;382:658. DOIPubMedGoogle Scholar
  7. Wagemakers  A, Koetsveld  J, Narasimhan  S, Wickel  M, Deponte  K, Bleijlevens  B, et al. Variable major proteins as targets for specific antibodies against Borrelia miyamotoi. J Immunol. 2016;196:418595. DOIPubMedGoogle Scholar
  8. Koetsveld  J, Kolyasnikova  NM, Wagemakers  A, Stukolova  OA, Hoornstra  D, Sarksyan  DS, et al. Serodiagnosis of Borrelia miyamotoi disease by measuring antibodies against GlpQ and variable major proteins. Clin Microbiol Infect. 2018;S1198-743X(18)30215-5.
  9. Sudhindra  P, Wang  G, Schriefer  ME, McKenna  D, Zhuge  J, Krause  PJ, et al. Insights into Borrelia miyamotoi infection from an untreated case demonstrating relapsing fever, monocytosis and a positive C6 Lyme serology. Diagn Microbiol Infect Dis. 2016;86:936. DOIPubMedGoogle Scholar
  10. Molloy  PJ, Weeks  KE, Todd  B, Wormser  GP. Seroreactivity to the C6 peptide in Borrelia miyamotoi infections occurring in the northeastern United States. Clin Infect Dis. 2018;66:140710. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid2409.180806

Original Publication Date: July 31, 2018

1These authors contributed equally to this article.

Table of Contents – Volume 24, Number 9—September 2018

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Dieuwertie Hoornstra, Academic Medical Center, Center for Experimental and Molecular Medicine, Meibergdreef 9 Amsterdam 1105 AZ, the Netherlands

Send To

10000 character(s) remaining.


Page created: August 17, 2018
Page updated: August 17, 2018
Page reviewed: August 17, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.